LATE BREAKING ABSTRACT: Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-...

Date 28 September 2015
Event European Cancer Congress 2015
Session Presidential Session III
Topics Small-Cell Lung Cancer
Presenter Pietanza, M.C.